CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
The novel long-acting insulin LY2605541 is superior to insulin glargine in lowering intra-day glucose variability and hypoglycemia event rate from Continuous Glucose Monitoring (CGM) in patients with type 2 diabetes*
DOI 10.1055/s-0033-1341827
Bibliografische Angaben
Nachweis in CareLit
Autor:innenEJ Bastyr, R Bergenstal, J Rosenstock, MJ Prince, Y Qu, SJ Jacober
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe04/2013
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Objectives: The basal insulin analog LY2605541 (LY) is PEGylated insulin lispro with a large hydrodynamic size which delays insulin absorption and reduces clearance, resulting in prolonged duration of action. Methodology: Hypoglycemia and glucose variability were assessed with CGM of interstitial glucose (IG) in a subset of patients from a Phase 2, randomized, open-label, parallel study of LY (n = 51) or insulin gla…
Zitieren
Zitierempfehlung
EJ Bastyr, R Bergenstal, J Rosenstock, MJ Prince, Y Qu, SJ Jacober (2013) The novel long-acting insulin LY2605541 is superior to insulin glargine in lowering intra-day glucose variability and hypoglycemia event rate from Continuous Glucose Monitoring (CGM) in patients with type 2 diabetes*. Diabetologie und Stoffwechsel (04). https://doi.org/10.1055/s-0033-1341827
Mit CareLit weiterarbeiten